Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.
Press releases published on June 2, 2025
Stratus Therapeutics Strengthens Executive Team with Appointment of Michael P. Cooke, PhD as Chief Scientific Officer
GlobeNewswire
·
June 2, 2025
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Stratus Therapeutics, Inc. (“Stratus”), a biotechnology company developing on-demand hematopoietic stem cell (HSC) therapies, today announced the appointment of Michael (Mike) P. Cooke, PhD, as Chief …
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
GlobeNewswire
·
June 2, 2025
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: …
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
GlobeNewswire
·
June 2, 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next- …
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
GlobeNewswire
·
June 2, 2025
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement …
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
GlobeNewswire
·
June 2, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical …
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewswire
·
June 2, 2025
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all …
Xilio Therapeutics Announces Proposed Public Offering
GlobeNewswire
·
June 2, 2025
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is …